Analysis of 35,000 patients tested with Nodify Lung® Nodule Risk Assessment in a real-world setting to be presented at CHEST 2024 and launch of a new clinical study designed to expand data package LOUISVILLE, Colo. --(BUSINESS WIRE)--Oct. 7, 2024-- Biodesix, Inc.

LOUISVILLE, Colo. --(BUSINESS WIRE)--Sep. 5, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team will present at two upcoming investor conferences: Lake Street Capital Markets 8 th

Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million ; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million ; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and

LOUISVILLE, Colo. --(BUSINESS WIRE)--Aug. 6, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will present in a fireside chat and host in-person 1x1 investor meetings

LOUISVILLE, Colo. --(BUSINESS WIRE)--Jul. 24, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it will release financial results for the second quarter ended June 30, 2024 after the close of trading on Wednesday, August 7 .

Awarding Excellence in Company Culture LOUISVILLE, Colo. --(BUSINESS WIRE)--Jun. 18, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive,

LOUISVILLE, Colo. --(BUSINESS WIRE)--May 28, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth

Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema LOUISVILLE, Colo. --(BUSINESS WIRE)--May 21, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented

First quarter 2024 Total Revenue of $14.8 million , a year-over-year increase of 64%, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume; First quarter 2024 gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023; Raised $55

LOUISVILLE, Colo. --(BUSINESS WIRE)--May 7, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will present and host in-person 1x1 investor meetings at the 2024 RBCCM